Rewards: Earn 2 miles for every dollar spent on cable and satellite providers, select telecommunications merchants, eligible American Airlines purchases, car rentals, and gas stations and 1 mile for every dollar spent on other purchases. Though it might not stack up against the heavy-duty-and expensive-top airline cards, it holds its own in the space for an annual fee of $99, waived for the first 12 months. The CitiBusiness® / AAdvantage® Platinum Select® Mastercard® * comes loaded with travel perks and earns solid rewards. In addition, the card has no foreign transaction fees and offers damage and theft protection on purchases, extended warranty, worldwide car rental insurance, worldwide travel accident insurance, special access to tickets through Citi Entertainment and a staff of experts to help with travel, shopping and more via Citi Concierge. This is potentially a limitation of the card since it greatly restricts your rewards, but if you shop frequently at Costco, it could be a plus. Costco Warehouses, including Puerto Rico. Other benefits and drawbacks: The Costco Anywhere Visa® Business Card by Citi * does not have a welcome bonus and in addition, cash back will be provided as an annual credit card reward certificate once per year in February, which is redeemable for cash or merchandise at U.S. Welcome offer: This card does not offer a welcome bonus. A Costco membership is required to apply. Rewards: Earn 4% cash back on eligible gas and EV charging purchases for the first $7,000 spent per year, 1% thereafter, unlimited 3% cash back on restaurants and eligible travel purchases, 2% cash back on purchases from Costco and and 1% cash back on all other purchases. Though it doesn’t have an annual fee, it does require a Costco membership, which can vary in price. CNBC's Michael Bloom contributed to this report.The Costco Anywhere Visa® Business Card by Citi * offers excellent capped rewards on gas and damage and theft-related purchase protection. Growth firms such as biotech and tech are more sensitive to any fluctuating costs of borrowing. "The speed and degree of interest rate increases have likely been the most influential factor in Biotech fluctuations, and any slowing in rate increases or reductions could rally the sector (especially in SMID-Biotech)," said BMO, referring to small and medium-sized biotech firms. The investment bank said it expects outperformance in biotech to be driven by flattening or declining interest rates "disproportionately benefiting high duration Biotech," and other high-profile catalysts. "Despite underperformance of the XBI, we see significant opportunity for investors to realize gains over the next 6-12 months," said BMO, referring to the SPDR S & P Biotech ETF. Outlook for biotech The biotech sector has faced headwinds since early 2022, as macroeconomic uncertainty, regulatory overhangs, and rapidly rising interest rates weigh, noted BMO Capital Markets in a Nov. On FactSet, the highest estimate came from Oppenheimer, which gives it potential upside of over 600%. According to FactSet, analysts covering the stock give it average price target upside of 385% and a buy rating of 88%. Citi isn't alone in its bullishness on the company. Biomea shares are around 18% higher year-to-date. Beyond diabetes, Biomea is also testing the treatment on leukemia and other cancers. Citi predicts a 65% probability of success for that trial, with $1.9 billion in risk-adjusted U.S. Citi noted that Biomea's initial data from its trial for a type 2 diabetes treatment - called BMF-219 -exceeded the bank's expectations. However, the bank cautioned that the stock is high risk, given the "typical volatility" of biotech stocks and uncertainty associated with clinical trials. 22 note, Citi gave the stock a buy rating and a price target of $90, representing potential upside of around 818% from Tuesday's price. These therapies offer "a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response," the company says. That company is U.S.-listed Biomea Fusion, which develops covalent therapies to treat cancers and metabolic diseases. Personal Loans for 670 Credit Score or LowerĬiti is so bullish on one biotech firm that it has given its shares a target price that represents around 800% upside. Personal Loans for 580 Credit Score or Lower Best Debt Consolidation Loans for Bad Credit
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |